CD4+ group 1 innate lymphoid cells (ILC) form a functionally distinct ILC subset that is increased in systemic sclerosis

Journal of Immunology

Volumn 196, Issue 5, 2016, Pages 2051-2062

  Roan, Florence ^a,b   Whalen, Elizabeth ^a   Molitor, Jerry A ^c   Bluestone, Jeffrey A ^d   Buckner, Jane H ^a   Ziegler, Steven F ^a  

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CELL SURFACE MARKER; CYTOKINE; INTERLEUKIN 6 RECEPTOR ALPHA; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2;

ARTICLE; BLOOD SAMPLING; CELL FUNCTION; CELL MATURATION; CELL MIGRATION; CELL SUBPOPULATION; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; INNATE IMMUNITY; LYMPHOID CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN BLOOD VESSEL DISORDER; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TH1 CELL; CD4+ T LYMPHOCYTE; CELL SEPARATION; DNA MICROARRAY; FLOW CYTOMETRY; IMMUNOLOGY; T LYMPHOCYTE SUBPOPULATION;

CD4-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; FLOW CYTOMETRY; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SCLERODERMA, SYSTEMIC; T-LYMPHOCYTE SUBSETS;

EID: 84962013426     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501491     Document Type: Article

References (79)

1. Nussbaum, J. C., S. J. Van Dyken, J. von Moltke, L. E. Cheng, A. Mohapatra, A. B. Molofsky, E. E. Thornton, M. F. Krummel, A. Chawla, H.-E. Liang, and R. M. Locksley. 2013. Type 2 innate lymphoid cells control eosinophil homeostasis. Nature 502: 245-248
2. Lee, M.-W., J. I. Odegaard, L. Mukundan, Y. Qiu, A. B. Molofsky, J. C. Nussbaum, K. Yun, R. M. Locksley, and A. Chawla. 2015. Activated type 2 innate lymphoid cells regulate beige fat biogenesis. Cell 160: 74-87
3. Brestoff, J. R., B. S. Kim, S. A. Saenz, R. R. Stine, L. A. Monticelli, G. F. Sonnenberg, J. J. Thome, D. L. Farber, K. Lutfy, P. Seale, and D. Artis. 2015. Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. Nature 519: 242-246
4. Van Gool, F., A. B. Molofsky, M. M. Morar, M. Rosenzwajg, H.-E. Liang, D. Klatzmann, R. M. Locksley, and J. A. Bluestone. 2014. Interleukin-5- producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. Blood 124: 3572-3576
5. Sawa, S., M. Lochner, N. Satoh-Takayama, S. Dulauroy, M. Bérard, M. Kleinschek, D. Cua, J. P. Di Santo, and G. Eberl. 2011. RORgt+ innate lymphoid cells regulate intestinal homeostasis by integrating negative signals from the symbiotic microbiota. Nat. Immunol. 12: 320-326
6. Goto, Y., T. Obata, J. Kunisawa, S. Sato, I. I. Ivanov, A. Lamichhane, N. Takeyama, M. Kamioka, M. Sakamoto, T. Matsuki, et al. 2014. Innate lymphoid cells regulate intestinal epithelial cell glycosylation. Science 345: 1254009
7. Hepworth, M. R., L. A. Monticelli, T. C. Fung, C. G. K. Ziegler, S. Grunberg, R. Sinha, A. R. Mantegazza, H.-L. Ma, A. Crawford, J. M. Angelosanto, et al. 2013. Innate lymphoid cells regulate CD4+ T-cell responses to intestinal commensal bacteria. Nature 498: 113-117
8. Mirchandani, A. S., A.-G. Besnard, E. Yip, C. Scott, C. C. Bain, V. Cerovic, R. J. Salmond, and F. Y. Liew. 2014. Type 2 innate lymphoid cells drive CD4+ Th2 cell responses. J. Immunol. 192: 2442-2448
9. Oliphant, C. J., Y. Y. Hwang, J. A. Walker, M. Salimi, S. H. Wong, J. M. Brewer, A. Englezakis, J. L. Barlow, E. Hams, S. T. Scanlon, et al. 2014. MHCII-mediated dialog between group 2 innate lymphoid cells and CD4(+) T cells potentiates type 2 immunity and promotes parasitic helminth expulsion. Immunity 41: 283-295
10. von Burg, N., S. Chappaz, A. Baerenwaldt, E. Horvath, S. Bose Dasgupta, D. Ashok, J. Pieters, F. Tacchini-Cottier, A. Rolink, H. Acha-Orbea, and D. Finke. 2014. Activated group 3 innate lymphoid cells promote T-cellmediated immune responses. Proc. Natl. Acad. Sci. USA 111: 12835-12840
11. Klose, C. S., E. A. Kiss, V. Schwierzeck, K. Ebert, T. Hoyler, Y. d'Hargues, N. Göppert, A. L. Croxford, A. Waisman, Y. Tanriver, and A. Diefenbach. 2013. A T-bet gradient controls the fate and function of CCR6-RORgt+ innate lymphoid cells. Nature 494: 261-265
12. Klose, C. S., M. Flach, L. Möhle, L. Rogell, T. Hoyler, K. Ebert, C. Fabiunke, D. Pfeifer, V. Sexl, D. Fonseca-Pereira, et al. 2014. Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages. Cell 157: 340-356
13. Neill, D. R., S. H. Wong, A. Bellosi, R. J. Flynn, M. Daly, T. K. Langford,C. Bucks, C. M. Kane, P. G. Fallon, R. Pannell, et al. 2010. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 464: 1367-1370
14. Monticelli, L. A., G. F. Sonnenberg, M. C. Abt, T. Alenghat, C. G. Ziegler, T. A. Doering, J. M. Angelosanto, B. J. Laidlaw, C. Y. Yang, T. Sathaliyawala, et al. 2011. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat. Immunol. 12: 1045-1054
15. Halim, T. Y., R. H. Krauss, A. C. Sun, and F. Takei. 2012. Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation. Immunity 36: 451-463
16. Klein Wolterink, R. G., A. Kleinjan, M. van Nimwegen, I. Bergen, M. de Bruijn, Y. Levani, and R. W. Hendriks. 2012. Pulmonary innate lymphoid cells are major producers of IL-5 and IL-13 in murine models of allergic asthma. Eur. J. Immunol. 42: 1106-1116
17. Buonocore, S., P. P. Ahern, H. H. Uhlig, I. I. Ivanov, D. R. Littman, K. J. Maloy, and F. Powrie. 2010. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 464: 1371-1375
18. Sonnenberg, G. F., L. A. Monticelli, M. M. Elloso, L. A. Fouser, and D. Artis. 2011. CD4(+) lymphoid tissue-inducer cells promote innate immunity in the gut. Immunity 34: 122-134
19. Perry, J. S., S. Han, Q. Xu, M. L. Herman, L. B. Kennedy, G. Csako, and B. Bielekova. 2012. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci. Transl. Med. 4: 145ra106
20. Dyring-Andersen, B., C. Geisler, C. Agerbeck, J. P. Lauritsen, S. D. Gúdjonsdottir, L. Skov, and C. M. Bonefeld. 2014. Increased number and frequency of group 3 innate lymphoid cells in nonlesional psoriatic skin. Br. J. Dermatol. 170: 609-616
21. Teunissen, M. B., J. M. Munneke, J. H. Bernink, P. I. Spuls, P. C. Res, A. Te Velde, S. Cheuk, M. W. Brouwer, S. P. Menting, L. Eidsmo, et al. 2014. Composition of innate lymphoid cell subsets in the human skin: enrichment of NCR (+) ILC3 in lesional skin and blood of psoriasis patients. J. Invest. Dermatol. 134: 2351-2360
22. Geremia, A., C. V. Arancibia-Cárcamo, M. P. Fleming, N. Rust, B. Singh, N. J. Mortensen, S. P. L. Travis, and F. Powrie. 2011. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J. Exp. Med. 208: 1127-1133
23. Mjösberg, J. M., S. Trifari, N. K. Crellin, C. P. Peters, C. M. van Drunen, B. Piet, W. J. Fokkens, T. Cupedo, and H. Spits. 2011. Human IL-25- and IL-33- responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat. Immunol. 12: 1055-1062
24. Kim, B. S., M. C. Siracusa, S. A. Saenz, M. Noti, L. A. Monticelli, G. F. Sonnenberg, M. R. Hepworth, A. S. Van Voorhees, M. R. Comeau, and D. Artis. 2013. TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci. Transl. Med. 5: 170ra16
25. Bartemes, K. R., G. M. Kephart, S. J. Fox, and H. Kita. 2014. Enhanced innate type 2 immune response in peripheral blood from patients with asthma. J. Allergy Clin. Immunol. 134: 671-678.e4
26. Barnig, C., M. Cernadas, S. Dutile, X. Liu, M. A. Perrella, S. Kazani, M. E. Wechsler, E. Israel, and B. D. Levy. 2013. Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma. Sci. Transl. Med. 5: 174ra26
27. Villanova, F., B. Flutter, I. Tosi, K. Grys, H. Sreeneebus, G. K. Perera, A. Chapman, C. H. Smith, P. Di Meglio, and F. O. Nestle. 2014. Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. J. Invest. Dermatol. 134: 984-991
28. Spits, H., D. Artis, M. Colonna, A. Diefenbach, J. P. Di Santo, G. Eberl, S. Koyasu, R. M. Locksley, A. N. J. McKenzie, R. E. Mebius, et al. 2013. Innate lymphoid cells-a proposal for uniform nomenclature. Nat. Rev. Immunol. 13: 145-149
29. Huntington, N. D., C. A. Vosshenrich, and J. P. Di Santo. 2007. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat. Rev. Immunol. 7: 703-714
30. Bernink, J. H., C. P. Peters, M. Munneke, A. A. te Velde, S. L. Meijer, K. Weijer, H. S. Hreggvidsdottir, S. E. Heinsbroek, N. Legrand, C. J. Buskens, et al. 2013. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat. Immunol. 14: 221-229
31. Bekiaris, V., J. R. -Sedy, M. Rossetti, R. Spreafico, S. Sharma, A. Rhode-Kurnow, B. C. Ware, N. Huang, M. G. Macauley, P. S. Norris, et al. 2013. Human CD4 +CD32 innate-like T cells provide a source of TNF and lymphotoxin-ab and are elevated in rheumatoid arthritis. J. Immunol. 191: 4611-4618
32. Lazarevic, V., L. H. Glimcher, and G. M. Lord. 2013. T-bet: a bridge between innate and adaptive immunity. Nat. Rev. Immunol. 13: 777-789
33. Knox, J. J., G. L. Cosma, M. R. Betts, and L. M. McLane. 2014. Characterization of T-bet and eomes in peripheral human immune cells. Front. Immunol. 5: 217
34. Yang, Y., J. Xu, Y. Niu, J. S. Bromberg, and Y. Ding. 2008. T-bet and eomesodermin play critical roles in directing T cell differentiation to Th1 versus Th17. J. Immunol. 181: 8700-8710
35. Pearce, E. L., A. C. Mullen, G. A. Martins, C. M. Krawczyk, A. S. Hutchins, V. P. Zediak, M. Banica, C. B. DiCioccio, D. A. Gross, C. A. Mao, et al. 2003. Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science 302: 1041-1043
36. Qin, S., J. B. Rottman, P. Myers, N. Kassam, M. Weinblatt, M. Loetscher, A. E. Koch, B. Moser, and C. R. Mackay. 1998. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest. 101: 746-754
37. Sallusto, F., D. Lenig, C. R. Mackay, and A. Lanzavecchia. 1998. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J. Exp. Med. 187: 875-883
38. Acosta-Rodriguez, E. V., L. Rivino, J. Geginat, D. Jarrossay, M. Gattorno, A. Lanzavecchia, F. Sallusto, and G. Napolitani. 2007. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 8: 639-646
39. Singh, S. P., H. H. Zhang, J. F. Foley, M. N. Hedrick, and J. M. Farber. 2008. Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J. Immunol. 180: 214-221
40. Duhen, T., R. Geiger, D. Jarrossay, A. Lanzavecchia, and F. Sallusto. 2009. Production of interleukin 22 but not interleukin 17 by a subset of human skinhoming memory T cells. Nat. Immunol. 10: 857-863
41. Duhen, T., R. Duhen, A. Lanzavecchia, F. Sallusto, and D. J. Campbell. 2012. Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood 119: 4430-4440
42. Trifari, S., C. D. Kaplan, E. H. Tran, N. K. Crellin, and H. Spits. 2009. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat. Immunol. 10: 864-871
43. Williams, I. R. 2004. Chemokine receptors and leukocyte trafficking in the mucosal immune system. Immunol. Res. 29: 283-292
44. Islam, S. A., and A. D. Luster. 2012. T cell homing to epithelial barriers in allergic disease. Nat. Med. 18: 705-715
45. Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14: 233-258
46. van Lier, R. A., J. Borst, T. M. Vroom, H. Klein, P. Van Mourik, W. P. Zeijlemaker, and C. J. Melief. 1987. Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen. J. Immunol. 139: 1589-1596
47. Moingeon, P., H. C. Chang, P. H. Sayre, L. K. Clayton, A. Alcover, P. Gardner, and E. L. Reinherz. 1989. The structural biology of CD2. Immunol. Rev. 111: 111-144
48. Sallusto, F., J. Geginat, and A. Lanzavecchia. 2004. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22: 745-763
49. Tanaka, T., M. Narazaki, and T. Kishimoto. 2014. IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 6: a016295
50. Huang, W., B. T. Sherman, and R. A. Lempicki. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4: 44-57
51. Huang, W., B. T. Sherman, and R. A. Lempicki. 2009. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37: 1-13
52. Abbas, A. R., D. Baldwin, Y. Ma, W. Ouyang, A. Gurney, F. Martin, S. Fong, M. van Lookeren Campagne, P. Godowski, P. M. Williams, et al. 2005. Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data. Genes Immun. 6: 319-331
53. Moris, A., S. Murray, and S. Cardinaud. 2014. AID and APOBECs span the gap between innate and adaptive immunity. Front. Microbiol. 5: 534
54. Gabrielli, A., E. V. Avvedimento, and T. Krieg. 2009. Scleroderma. N. Engl. J. Med. 360: 1989-2003
55. Barron, L., and T. A. Wynn. 2011. Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. Am. J. Physiol. Gastrointest. Liver Physiol. 300: G723-G728
56. Radstake, T. R., L. van Bon, J. Broen, A. Hussiani, R. Hesselstrand, D. M.Wuttge, Y. Deng, R. Simms, E. Lubberts, and R. Lafyatis. 2009. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One 4: e5903
57. Truchetet, M.-E., N. C. Brembilla, E. Montanari, Y. Allanore, and C. Chizzolini. 2011. Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res. Ther. 13: R166
58. Mathian, A., C. Parizot, K. Dorgham, S. Trad, L. Arnaud, M. Larsen, M. Miyara, M. Hié, J.-C. Piette, C. Frances, et al. 2012. Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. Ann. Rheum. Dis. 71: 1227-1234
59. Hasegawa, M., S. Sato, M. Fujimoto, H. Ihn, K. Kikuchi, and K. Takehara. 1998. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J. Rheumatol. 25: 308-313
60. De Lauretis, A., P. Sestini, P. Pantelidis, R. Hoyles, D. M. Hansell, N. S. Goh, C. J. Zappala, D. Visca, T. M. Maher, C. P. Denton, et al. 2013. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J. Rheumatol. 40: 435-446
61. Needleman, B. W., F. M. Wigley, and R. W. Stair. 1992. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum. 35: 67-72
62. Phillips, J. H., T. Hori, A. Nagler, N. Bhat, H. Spits, and L. L. Lanier. 1992. Ontogeny of human natural killer (NK) cells: fetal NK cells mediate cytolytic function and express cytoplasmic CD3 epsilon,delta proteins. J. Exp. Med. 175: 1055-1066
63. Lanier, L. L., C. Chang, H. Spits, and J. H. Phillips. 1992. Expression of cytoplasmic CD3 epsilon proteins in activated human adult natural killer (NK) cells and CD3 gamma, delta, epsilon complexes in fetal NK cells. Implications for the relationship of NK and T lymphocytes. J. Immunol. 149: 1876-1880
64. Biassoni, R., S. Ferrini, I. Prigione, A. Moretta, and E. O. Long. 1988. CD3- negative lymphokine-activated cytotoxic cells express the CD3 epsilon gene. J. Immunol. 140: 1685-1689
65. Mueller, S. N., T. Gebhardt, F. R. Carbone, and W. R. Heath. 2013. Memory T cell subsets, migration patterns, and tissue residence. Annu. Rev. Immunol. 31: 137-161
66. Förster, R., A. Schubel, D. Breitfeld, E. Kremmer, I. Renner-Müller, E. Wolf, and M. Lipp. 1999. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99: 23-33
67. Gunn, M. D., S. Kyuwa, C. Tam, T. Kakiuchi, A. Matsuzawa, L. T. Williams, and H. Nakano. 1999. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J. Exp. Med. 189: 451-460
68. Crellin, N. K., S. Trifari, C. D. Kaplan, T. Cupedo, and H. Spits. 2010. Human NKp44+IL-22+ cells and LTi-like cells constitute a stable RORC+ lineage distinct from conventional natural killer cells. J. Exp. Med. 207: 281-290
69. Bromley, S. K., S. Yan, M. Tomura, O. Kanagawa, and A. D. Luster. 2013. Recirculating memory T cells are a unique subset of CD4+ T cells with a distinct phenotype and migratory pattern. J. Immunol. 190: 970-976
70. Aliprantis, A. O., J. Wang, J. W. Fathman, R. Lemaire, D. M. Dorfman, R. Lafyatis, and L. H. Glimcher. 2007. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc. Natl. Acad. Sci. USA 104: 2827-2830
71. Croft, M., C. A. Benedict, and C. F. Ware. 2013. Clinical targeting of the TNF and TNFR superfamilies. Nat. Rev. Drug Discov. 12: 147-168
72. van Nieuwenhuijze, A., M. Koenders, D. Roeleveld, M. A. Sleeman, W. van den Berg, and I. P. Wicks. 2013. GM-CSF as a therapeutic target in inflammatory diseases. Mol. Immunol. 56: 675-682
73. Sato, S., M. Hasegawa, and K. Takehara. 2001. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J. Dermatol. Sci. 27: 140-146
74. Khan, K., S. Xu, S. Nihtyanova, E. Derrett-Smith, D. Abraham, C. P. Denton, and V. H. Ong. 2012. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann. Rheum. Dis. 71: 1235-1242
75. Rose-John, S. 2012. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int. J. Biol. Sci. 8: 1237-1247
76. Jones, G. W., R. M. McLoughlin, V. J. Hammond, C. R. Parker, J. D. Williams, R. Malhotra, J. Scheller, A. S. Williams, S. Rose-John, N. Topley, and S. A. Jones. 2010. Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. J. Immunol. 184: 2130-2139
77. Elhai, M., M. Meunier, M. Matucci-Cerinic, B. Maurer, G. Riemekasten, T. Leturcq, R. Pellerito, C. A. Von Mühlen, A. Vacca, P. Airo, et al; EUSTAR (EULAR Scleroderma Trials and Research group). 2013. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann. Rheum. Dis. 72: 1217-1220
78. Chakravarty, E. F., DFiorentino, MBennett, and L. Chung. 2011. A Pilot Study of Abatacept for the Treatment of Patients with Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheum. 63 (Abstract Suppl.): 707
79. de Paoli, F. V., B. D. Nielsen, F. Rasmussen, B. Deleuran, and K. Søndergaard. 2014. Abatacept induces clinical improvement in patients with severe systemic sclerosis. Scand. J. Rheumatol. 43: 342-345